Abbott Q3 sales rise 6.9%; adj. EPS $1.30; reaffirms FY guidance

ABBOTT LABORATORIES

2025-Q3 EPS reported $2.70 revenue$32,869,000,000

GAAP diluted EPS $0.94; adjusted diluted EPS $1.30; reported sales $11.37B, organic growth 5.5% (7.5% ex-COVID testing).
Medical Devices up 14.8% reported, led by Diabetes Care CGM sales of $2.0B (+20.5% reported, +17.2% organic).
FY2025 organic sales guidance reaffirmed at 7.5-8.0% ex-COVID; adjusted EPS narrowed to $5.12-$5.18 (midpoint double-digit growth).
Adjusted operating margin improved 40bps to 23.0% of sales.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.